Your browser doesn't support javascript.
loading
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types.
Cristescu, Razvan; Nebozhyn, Michael; Zhang, Chunsheng; Albright, Andrew; Kobie, Julie; Huang, Lingkang; Zhao, Qing; Wang, Anran; Ma, Hua; Alexander Cao, Z; Morrissey, Michael; Ribas, Antoni; Grivas, Petros; Cescon, David W; McClanahan, Terrill K; Snyder, Alexandra; Ayers, Mark; Lunceford, Jared; Loboda, Andrey.
Affiliation
  • Cristescu R; Merck & Co., Inc., Kenilworth, New Jersey.
  • Nebozhyn M; Merck & Co., Inc., Kenilworth, New Jersey.
  • Zhang C; Merck & Co., Inc., Kenilworth, New Jersey.
  • Albright A; Merck & Co., Inc., Kenilworth, New Jersey.
  • Kobie J; Merck & Co., Inc., Kenilworth, New Jersey.
  • Huang L; Merck & Co., Inc., Kenilworth, New Jersey.
  • Zhao Q; Merck & Co., Inc., Kenilworth, New Jersey.
  • Wang A; Merck & Co., Inc., Kenilworth, New Jersey.
  • Ma H; Merck & Co., Inc., Kenilworth, New Jersey.
  • Alexander Cao Z; Merck & Co., Inc., Kenilworth, New Jersey.
  • Morrissey M; Merck & Co., Inc., Kenilworth, New Jersey.
  • Ribas A; Department of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Grivas P; University of Washington Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Cescon DW; UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • McClanahan TK; Merck & Co., Inc., Kenilworth, New Jersey.
  • Snyder A; Merck & Co., Inc., Kenilworth, New Jersey.
  • Ayers M; Merck & Co., Inc., Kenilworth, New Jersey.
  • Lunceford J; Merck & Co., Inc., Kenilworth, New Jersey.
  • Loboda A; Merck & Co., Inc., Kenilworth, New Jersey.
Clin Cancer Res ; 28(8): 1680-1689, 2022 04 14.
Article in En | MEDLINE | ID: mdl-34965943
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Agents, Immunological / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Agents, Immunological / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Type: Article